A review of patient self-report tools for chemotherapy-induced nausea and vomiting

Goals of workThe assessment of chemotherapy-induced nausea, vomiting and retching (CINVR) is important and to date no review has comprehensively assessed available patient self-report tools. The aim was to undertake a review of their utility, content and psychometric properties.Materials and methodsOne thousand three hundred and forty-seven citations were identified by electronic and hand searches resulting in 24 non-duplicate abstracts, 15 articles for analysis, and six articles, which fitted the inclusion criteria. E-mail investigations discovered a further scale, resulting in seven measures.ResultsThe review highlighted the strengths and weaknesses of current tools. The multiple domains, phases and aspects of CINVR signify that the assessment tools varied markedly. The diverse requirements of research and clinicians also contribute to the variation. There was a notable disparity in the quality of scales and paucity in terms of their development and psychometric evaluation. We found that several self-assessment scales currently perceived as well-validated tools have problems in terms of their validity, reliability and appropriateness.ConclusionsThe constituents of a scale relevant for both clinical and research use were assessed and it was recommended that a modular tool focusing on two domains (nausea and vomiting); two phases (acute and delayed); measuring the aspects of occurrence, frequency, intensity alongside duration and functional interference; and antiemetic use and adverse events should be developed. Based on these recommendations, further research into an appropriate scale would minimise conceptual confusion, increase clinicians’ understanding and control of CINVR, decrease patient distress and could have equal utility in both a clinical and a research setting.

[1]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[2]  M. Johnson,et al.  Development of reliable and valid measures of nausea and vomiting , 1984, Cancer nursing.

[3]  A McMurray,et al.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Morrow Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. , 1984, Cancer.

[5]  C. Presant Quality of life in cancer patients. Who measures what? , 1984, American journal of clinical oncology.

[6]  [Nausea and vomiting]. , 1987, Rivista dell'infermiere.

[7]  P. Brantley,et al.  Test-retest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy-related nausea and vomiting , 1988 .

[8]  D. Streiner,et al.  Health Measurement Scales: A practical guide to thier development and use , 1989 .

[9]  C. L. M. Carnike, Jr.,et al.  Assessing Nausea and Vomiting in Adult Chemotherapy Patients: Review and Recommendations , 1990 .

[10]  G. Morrow A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). , 1992, The British journal of cancer. Supplement.

[11]  D L Streiner,et al.  A checklist for evaluating the usefulness of rating scales. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[12]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[13]  D. Osoba Lessons learned from measuring health-related quality of life in oncology. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Matthews,et al.  The roles of patient and observer assessments in anti-emetic trials. , 1994, European journal of cancer.

[15]  S. Madajewicz,et al.  Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. , 1996, Clinical therapeutics.

[16]  P. Butow,et al.  On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. Kiltie,et al.  Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy , 1997, Supportive Care in Cancer.

[18]  M. Frank-Stromborg,et al.  Instruments for clinical health-care research , 1997 .

[19]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[20]  A. Depierre,et al.  The efficacy of a combination of ondansetron, methyiprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy , 1997 .

[21]  D. Osoba,et al.  Effect of postchemotherapy nausea and vomiting on health-related quality of life , 1997, Supportive Care in Cancer.

[22]  K. Colgan,et al.  Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  D. Osoba,et al.  Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Kris,et al.  Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Tonato,et al.  Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity , 1998, Supportive Care in Cancer.

[26]  Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  S. McMillan,et al.  Quality of life in cancer patients: use of a revised Hospice Index. , 1998, Cancer Practice.

[28]  L. Sarna Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. , 1998, Oncology nursing forum.

[29]  R. Stern,et al.  Use of 5‐HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings , 1999 .

[30]  L. Hayman,et al.  Parents associated with children in measuring acute and delayed nausea and vomiting. , 1999, Nursing & health sciences.

[31]  R. McDaniel,et al.  The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. , 1999, Oncology nursing forum.

[32]  Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. , 1999, Cancer.

[33]  Kunihiko Kobayashi,et al.  Effects of anti‐emetic drug (tropisetron) on quality of life during chemotherapy: Use of a diary‐type questionnaire and application of summary measures for assessment in a randomized, multicentre study , 1999, Respirology.

[34]  R. Stern,et al.  Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. , 2000, Journal of pain and symptom management.

[35]  J. Chapman,et al.  Acupressure for nausea: results of a pilot study. , 2000, Oncology nursing forum.

[36]  Ji-Young Kim,et al.  The Index of Nausea, Vomiting, and Retching(Korean Translation) , 2000 .

[37]  A. Molassiotis,et al.  The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial , 2002, Supportive Care in Cancer.

[38]  [Development of a Japanese version of the FLIE]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[39]  M. Fu,et al.  The Chinese Translation of the Index of Nausea, Vomiting, and Retching , 2002, Cancer nursing.

[40]  J. Luce,et al.  Delayed chemotherapy-induced nausea in women treated for breast cancer. , 2003, Oncology nursing forum.

[41]  J. Pearson,et al.  Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall , 2003, Supportive Care in Cancer.

[42]  Charles G. Martin,et al.  Measuring chemotherapy‐induced nausea and emesis , 2003, Cancer.

[43]  J. Atkins,et al.  Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics , 2003, Cancer.

[44]  J. Pearson,et al.  Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. , 2003, European journal of cancer.

[45]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[46]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  N. Kearney,et al.  Chemotherapy-related nausea and vomiting - past reflections, present practice and future management. , 2004, European journal of cancer care.

[48]  A. Hüsler,et al.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective , 2004, Supportive Care in Cancer.

[49]  G. de Pouvourville,et al.  Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.

[50]  M. Mori,et al.  How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Manfred Stommel,et al.  Symptom clusters in elderly patients with lung cancer. , 2004, Oncology nursing forum.

[52]  J. Osterhaus,et al.  Quality of life consequences of chemotherapy-induced emesis , 1992, Quality of Life Research.

[53]  Howard S. Smith,et al.  A Receptor-Based Paradigm of Nausea and Vomiting , 2005 .

[54]  N. Kearney,et al.  Nursing Patients with Cancer. Principles and Practice. , 2005 .

[55]  S. Kuo,et al.  Assessing the Psychometric and Language Equivalency of the Chinese Versions of the Index of Nausea, Vomiting and Retching, and the Prenatal Self‐evaluation Questionnaire , 2005, The Kaohsiung journal of medical sciences.

[56]  A. Molassiotis,et al.  Nausea and vomiting , 2006 .

[57]  L. Schwartzberg Chemotherapy-induced nausea and vomiting: state of the art in 2006. , 2006, The journal of supportive oncology.

[58]  E. Demeyer,et al.  Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. , 2006, The journal of supportive oncology.

[59]  M. Huschka,et al.  Does QOL provide the same information as toxicity data? , 2006, Current problems in cancer.

[60]  K. Bergkvist,et al.  Symptom experiences during chemotherapy treatment--with focus on nausea and vomiting. , 2006, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[61]  A. Molassiotis,et al.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre , 2008, Supportive Care in Cancer.

[62]  A. Molassiotis,et al.  The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. , 2007, Complementary therapies in medicine.

[63]  S. Beck,et al.  Treatment-related symptom clusters. , 2007, Seminars in oncology nursing.

[64]  C. Clements,et al.  Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. , 2007, Journal of pain and symptom management.

[65]  E. Waclawski Health Measurement Scales—A Practical Guide to Their Development and Use , 2010 .